December 20, 2021
Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma
Media
December 16, 2021
Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma
December 16, 2021
Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer
December 15, 2021
Targovax awarded NOK 9.8m research grant by the Research Council of Norway towards the TG mutant RAS program
December 15, 2021
Doctrin makes strategic recruitments to support further expansion – Jesper Eriksson joins as new CFO and Michael Ekelund as CCO
December 15, 2021
Targovax ASA – Final results of the rights issue
December 14, 2021
HelloBetter Diabetes and Depression – new therapy option for psychologically stressed people with diabetes now available on prescription
December 14, 2021
Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting
December 13, 2021
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
December 10, 2021
Oncopeptides presents new melflufen data at the Annual American Society of Hematology Meeting ASH